

## Special Issue

# Lymphocyte Migration in Solid Tumors

### Message from the Guest Editor

Several studies have provided evidence that the frequency of tumor-infiltrating T and NK cells is associated with a good prognosis and potentially even predicts response to therapy in patients with solid tumors. The migration of lymphocytes is governed by chemokines, which consist of small secreted polypeptides. Attempts to modulate the tumor microenvironment to produce chemokines to attract T and NK cells or the modulation of ex vivo expanded lymphocytes to express chemokine receptors have provided evidence of increased lymphocyte infiltration in solid tumors. This Special Issue focuses on several aspects to improve lymphocyte migration into solid tumors. Specific topics include but are not limited to manipulation of T and NK cells to express chemokine receptors, manipulation of the tumor microenvironment to attract T and NK cells, and cross-talk with tissue-resident cells to augment tumor infiltration of T and NK cells.

---

### Guest Editor

Dr. Andreas Lundqvist

Department of Oncology-Pathology, Karolinska Institutet, S-17164 Stockholm, Sweden

---

### Deadline for manuscript submissions

closed (31 December 2020)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/44370](https://mdpi.com/si/44370)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)